Demographic characteristics of our cohort at first visit
| Variable | Total N=867 | EULAR/ACR score<20 N=415 | EULAR/ACR score≥20 N=452 | P value |
| Sex | ||||
| Female | 759 (87.5) | 364 (87.7) | 395 (87.4) | 0.866 |
| Male | 108 (12.5) | 51 (12.3) | 57 (12.6) | |
| Race | <0.001 | |||
| Caucasian | 578 (66.7) | 316 (76.1) | 262 (58.0) | |
| Black | 123 (14.2) | 42 (10.1) | 81 (17.9) | |
| Chinese | 72 (8.3) | 20 (4.8) | 52 (11.5) | |
| Others | 40 (4.6) | 15 (3.6) | 25 (5.5) | |
| Native North American | 3 (0.3) | 1 (0.2) | 2 (0.4) | |
| Filipino | 38 (4.4) | 15 (3.6) | 23 (5.1) | |
| Mixed | 10 (1.2) | 4 (1.0) | 6 (1.3) | |
| Age (years) | 36.2±14.2 | 38.1±15.1 | 34.5±13.1 | <0.001 |
| Disease duration (years) | 0.2±0.3 | 0.2±0.3 | 0.2±0.3 | 0.866 |
| SLEDAI-2K score | 9.4±8.0 | 6.3±5.4 | 12.2±8.9 | <0.001 |
| SLICC Damage Index | 0.1±0.4 | 0.1±0.4 | 0.1±0.4 | 0.133 |
| Therapy | ||||
| Glucocorticoids at first visit | 487 (56.2) | 185 (44.6) | 302 (66.8) | <0.001 |
| Antimalarials at first visit | 321 (37.0) | 151 (36.4%) | 170 (37.6) | 0.709 |
| Immunosuppressives at first visit | 151 (17.4) | 58 (14) | 93 (20.6) | 0.010 |
Values are expressed as mean±SD or n (%).
Bold face p values denote statistical significance.
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC, Systemic Lupus International Collaborating Clinics.